209 related articles for article (PubMed ID: 34865086)
1. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.
Goldberg RM; Adams R; Buyse M; Eng C; Grothey A; André T; Sobrero AF; Lichtman SM; Benson AB; Punt CJA; Maughan T; Burzykowski T; Sommeijer D; Saad ED; Shi Q; Coart E; Chibaudel B; Koopman M; Schmoll HJ; Yoshino T; Taieb J; Tebbutt NC; Zalcberg J; Tabernero J; Van Cutsem E; Matheson A; de Gramont A
J Natl Cancer Inst; 2022 Jun; 114(6):819-828. PubMed ID: 34865086
[TBL] [Abstract][Full Text] [Related]
2. [Integration Process of Clinical Trial Data in ARCAD-Asia].
Bando H; Takeda Y; Misumi T; Suzuki M; Wakabayashi M; Ohtsu A; Yoshino T
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1021-1026. PubMed ID: 38035827
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
van Rooijen KL; Shi Q; Goey KKH; Meyers J; Heinemann V; Diaz-Rubio E; Aranda E; Falcone A; Green E; de Gramont A; Sargent DJ; Punt CJA; Koopman M
Eur J Cancer; 2018 Mar; 91():99-106. PubMed ID: 29353165
[TBL] [Abstract][Full Text] [Related]
4. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.
Renfro LA; Goldberg RM; Grothey A; Sobrero A; Adams R; Seymour MT; Heinemann V; Schmoll HJ; Douillard JY; Hurwitz H; Fuchs CS; Diaz-Rubio E; Porschen R; Tournigand C; Chibaudel B; Hoff PM; Kabbinavar FF; Falcone A; Tebbutt NC; Punt CJA; Hecht JR; Souglakos J; Bokemeyer C; Van Cutsem E; Saltz L; de Gramont A; Sargent DJ;
J Clin Oncol; 2017 Jun; 35(17):1929-1937. PubMed ID: 28414610
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
7. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.
Franko J; Yin J; Adams RA; Zalcberg J; Fiskum J; Van Cutsem E; Goldberg RM; Hurwitz H; Bokemeyer C; Kabbinavar F; Curtis A; Meyers J; Chibaudel B; Yoshino T; de Gramont A; Shi Q;
Eur J Cancer; 2022 Oct; 174():142-152. PubMed ID: 35994794
[TBL] [Abstract][Full Text] [Related]
8. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.
Lieu CH; Renfro LA; de Gramont A; Meyers JP; Maughan TS; Seymour MT; Saltz L; Goldberg RM; Sargent DJ; Eckhardt SG; Eng C;
J Clin Oncol; 2014 Sep; 32(27):2975-84. PubMed ID: 25002720
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Franko J; Shi Q; Meyers JP; Maughan TS; Adams RA; Seymour MT; Saltz L; Punt CJA; Koopman M; Tournigand C; Tebbutt NC; Diaz-Rubio E; Souglakos J; Falcone A; Chibaudel B; Heinemann V; Moen J; De Gramont A; Sargent DJ; Grothey A;
Lancet Oncol; 2016 Dec; 17(12):1709-1719. PubMed ID: 27743922
[TBL] [Abstract][Full Text] [Related]
10. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
Michiels S; Saad ED; Buyse M
Drugs; 2017 May; 77(7):713-719. PubMed ID: 28337673
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
12. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
Shi Q; de Gramont A; Grothey A; Zalcberg J; Chibaudel B; Schmoll HJ; Seymour MT; Adams R; Saltz L; Goldberg RM; Punt CJ; Douillard JY; Hoff PM; Hecht JR; Hurwitz H; Díaz-Rubio E; Porschen R; Tebbutt NC; Fuchs C; Souglakos J; Falcone A; Tournigand C; Kabbinavar FF; Heinemann V; Van Cutsem E; Bokemeyer C; Buyse M; Sargent DJ
J Clin Oncol; 2015 Jan; 33(1):22-8. PubMed ID: 25385741
[TBL] [Abstract][Full Text] [Related]
13. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
14. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
15. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
[TBL] [Abstract][Full Text] [Related]
16. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
[TBL] [Abstract][Full Text] [Related]
17. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials.
Pasalic D; McGinnis GJ; Fuller CD; Grossberg AJ; Verma V; Mainwaring W; Miller AB; Lin TA; Jethanandani A; Espinoza AF; Diefenhardt M; Das P; Subbiah V; Subbiah IM; Jagsi R; Garden AS; Fokas E; Rödel C; Thomas CR; Minsky BD; Ludmir EB
Eur J Cancer; 2020 Sep; 136():176-185. PubMed ID: 32702645
[TBL] [Abstract][Full Text] [Related]
19. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.
Renfro LA; Loupakis F; Adams RA; Seymour MT; Heinemann V; Schmoll HJ; Douillard JY; Hurwitz H; Fuchs CS; Diaz-Rubio E; Porschen R; Tournigand C; Chibaudel B; Falcone A; Tebbutt NC; Punt CJ; Hecht JR; Bokemeyer C; Van Cutsem E; Goldberg RM; Saltz LB; de Gramont A; Sargent DJ; Lenz HJ
J Clin Oncol; 2016 Jan; 34(2):144-50. PubMed ID: 26503203
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]